肝细胞癌III期试验中非比例风险的应对策略
该研究回顾2008至2024年肝细胞癌III期随机对照试验,用Grambsch-Therneau法检验比例风险假设。20项试验中4项(20%)存在非比例风险,均涉及免疫治疗,表现为效应递减、延迟效应和风险交叉三种模式。IMbrave050中期与最终分析结果不一致,提示非比例风险下需保证足够随访时间或事件数再行中期分析。
要点
- 肝细胞癌III期免疫治疗试验中20%存在非比例风险,可致中期与最终分析结论不一致。
- 非比例风险下中期分析需至少60%事件数或对照中位终点两倍随访时间。
- 推荐用MaxCombo检验判断组间差异,用rRMST和分段风险比评估效应大小。
核心结论
- 非比例风险可导致肝细胞癌随机对照试验中期与最终分析结果不一致,尤其见于免疫治疗试验。
- 存在非比例风险时,应保证足够随访时间或事件数再行中期分析,并采用MaxCombo、rRMST和分段风险比等稳健统计方法。
研究设计与样本
- 回顾性分析2008至2024年肝细胞癌III期关键随机对照试验,共纳入20项。
- 采用Grambsch-Therneau法检验比例风险假设,对存在非比例风险的试验提出中期分析时机和最低事件阈值。
主要发现
- 20项III期试验中4项(20%)存在非比例风险,均涉及免疫治疗,表现为效应递减、延迟效应和风险交叉三种模式。
- IMbrave050中期与最终分析在MaxCombo检验(p=0.02与p=0.33)、12和36个月rRMST(1.11 [p<0.001]与1.08 [p=0.08])及12个月前后的分段风险比(0.59 [95%CI 0.43-0.73]与1.12 [95%CI 0.88-1.37])上均不一致。
- LEAP-012在12和24个月结果一致(MaxCombo检验p<0.001;rRMST 1.20 [p<0.001]和1.27 [p<0.001])。
- HIMALAYA显示延迟效应(12和36个月rRMST:1.04 [p=0.13]和1.15 [p=0.004]),CheckMate 9DW显示风险交叉(12和36个月rRMST:0.95 [p=0.07]和1.12 [p=0.03])。
关键数值与推荐
- 对存在非比例风险的试验,建议中期分析时机为对照臂主要终点估计中位数的两倍,或最低事件阈值≥60%。
- 非比例风险场景下推荐采用MaxCombo检验判断组间差异,采用rRMST和分段风险比评估效应大小。
临床怎么用
- 肝细胞癌免疫治疗试验设计时应预先考虑非比例风险,避免在随访不足或事件数不够时提前终止试验。
- 中期分析发现非比例风险时,应改用MaxCombo、rRMST和分段风险比等稳健方法解读结果,而非仅依赖传统比例风险模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Non-proportional hazards (NPH) can lead to discrepancies between interim (IA) and final analyses (FA) in randomized controlled trials (RCTs) of hepatocellular carcinoma (HCC). We assessed the impact of NPH in pivotal HCC trials and proposed strategies for more robust analyses. METHODS: Phase III pivotal HCC RCTs (2008-2024) were reviewed. Proportional hazards were tested using the Grambsch-Therneau method. For trials with NPH, we proposed an optimal IA timing (twice the estimated median of the primary endpoint in the control arm) or a minimum event threshold (≥60%). In NPH scenarios, the MaxCombo test, restricted mean survival time (rRMST), and piecewise hazard ratios were applied. RESULTS: NPH was present in 4/20 (20%) phase III trials in HCC, all involving immunotherapies, and displayed three patterns: 1) diminishing effects, 2) delayed effects, and 3) crossing hazards. Two RCTs (IMbrave050, LEAP-012) reported positive IA results with diminishing effects. In IMbrave050, discrepancies were observed when comparing IA and FA using MaxCombo analysis (p = 0.02 and p = 0.33, respectively), rRMST at 12 and 36 months (1.11 [p <0.001] and 1.08 [p = 0.08], respectively) and piecewise hazard ratios before vs. after 12 months (0.59 [95% CI 0.43-0.73] vs. 1.12 [95% CI 0.88-1.37]). In LEAP-012, results were consistent across 12 and 24 months (MaxCombo test p <0.001) and rRMST (1.20 [p <0.001) and 1.27 [p <0.001]). HIMALAYA and Checkmate 9DW reported positive results, which were confirmed by MaxCombo test. HIMALAYA showed delayed effects (rRMST at 12 and 36 months: 1.04 [p = 0.13] and 1.15 [p = 0.004]), while CheckMate 9DW displayed crossing hazards (rRMST at 12 and 36 months: 0.95 [p = 0.07] and 1.12 [p = 0.03]). CONCLUSION: NPH contributed to discrepancies between IA and FA in IMbrave050. Robust IA require a minimum follow-up duration or event count before prematurely stopping RCTs in the presence of NPH. IMPACT AND IMPLICATIONS: Non-proportional hazards (NPH) impact phase III randomized controlled trials in hepatocellular carcinoma, particularly in immunotherapy trials, potentially causing discrepancies between the interim and final analyses. In fact, halting trials at the interim analysis can be premature when NPH is present. Thus, we propose a framework to ensure study maturity based on follow-up duration and event accruals to optimize interim analyses in the presence of NPH. Whenever NPH is identified, distinct statistical tools should be used to assess reliable differences between arms (MaxCombo) and to assess the effect size (restricted mean survival time and piecewise hazard ratios) for regulatory decisions and clinical guidance. Implementing these strategies can improve trial design, and better support clinical decision-making.
引用
- Mauro E, de Castro T, Zeitlhoefler M, et al. Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma. J Hepatol. 2025. PMID: 40992574. doi:10.1016/j.jhep.2025.08.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。